Coherus Biosciences (CHRS) – Analysts’ Recent Ratings Updates

Coherus Biosciences (NASDAQ: CHRS) has recently received a number of price target changes and ratings updates:

  • 6/24/2019 – Coherus Biosciences was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 6/21/2019 – Coherus Biosciences was given a new $30.00 price target on by analysts at Barclays PLC. They now have a “buy” rating on the stock.
  • 6/19/2019 – Coherus Biosciences was given a new $28.00 price target on by analysts at Robert W. Baird. They now have a “buy” rating on the stock.
  • 6/17/2019 – Coherus Biosciences was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 6/11/2019 – Coherus Biosciences is now covered by analysts at Barclays PLC. They set an “overweight” rating and a $30.00 price target on the stock.
  • 6/11/2019 – Coherus Biosciences was downgraded by analysts at BidaskClub from a “strong-buy” rating to a “buy” rating.
  • 5/20/2019 – Coherus Biosciences was upgraded by analysts at BidaskClub from a “buy” rating to a “strong-buy” rating.
  • 5/18/2019 – Coherus Biosciences was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating.
  • 5/15/2019 – Coherus Biosciences was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $19.00 price target on the stock. According to Zacks, “Coherus Biosciences, Inc. is a biologics platform company developing biosimilar therapeutics. Its clinical stage pipeline consists of CHS-0214 in two Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis; CHS-1420 that has completed a Phase I study to treat psoriasis or rheumatoid arthritis; and CHS-1701 which has completed a Phase I study for the treatment of breast cancer patients. Coherus Biosciences, Inc. is headquartered in Redwood City, California. “
  • 5/10/2019 – Coherus Biosciences was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Coherus Biosciences, Inc. is a biologics platform company developing biosimilar therapeutics. Its clinical stage pipeline consists of CHS-0214 in two Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis; CHS-1420 that has completed a Phase I study to treat psoriasis or rheumatoid arthritis; and CHS-1701 which has completed a Phase I study for the treatment of breast cancer patients. Coherus Biosciences, Inc. is headquartered in Redwood City, California. “
  • 5/10/2019 – Coherus Biosciences was given a new $25.00 price target on by analysts at Maxim Group. They now have a “buy” rating on the stock.
  • 5/10/2019 – Coherus Biosciences was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating.
  • 5/7/2019 – Coherus Biosciences is now covered by analysts at HC Wainwright. They set a “buy” rating and a $28.00 price target on the stock.
  • 5/4/2019 – Coherus Biosciences was downgraded by analysts at ValuEngine from a “buy” rating to a “hold” rating.
  • 4/30/2019 – Coherus Biosciences was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.

Shares of CHRS stock opened at $21.14 on Wednesday. The company has a quick ratio of 3.79, a current ratio of 3.84 and a debt-to-equity ratio of 8.29. Coherus Biosciences Inc has a 1 year low of $8.32 and a 1 year high of $22.03. The stock’s fifty day simple moving average is $18.86. The firm has a market cap of $1.48 billion, a price-to-earnings ratio of -6.57 and a beta of 3.17.

Coherus Biosciences (NASDAQ:CHRS) last announced its quarterly earnings results on Thursday, May 9th. The biotechnology company reported ($0.29) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.45) by $0.16. The business had revenue of $37.10 million for the quarter, compared to analyst estimates of $36.83 million. As a group, analysts predict that Coherus Biosciences Inc will post -0.19 EPS for the current year.

In other news, CFO Jean-Frederic Viret sold 6,826 shares of the company’s stock in a transaction on Wednesday, June 19th. The stock was sold at an average price of $19.85, for a total value of $135,496.10. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Dennis M. Lanfear sold 32,398 shares of the company’s stock in a transaction on Thursday, May 30th. The shares were sold at an average price of $19.49, for a total value of $631,437.02. Following the completion of the sale, the chief executive officer now owns 125,017 shares of the company’s stock, valued at approximately $2,436,581.33. The disclosure for this sale can be found here. In the last 90 days, insiders sold 614,224 shares of company stock valued at $12,879,332. Insiders own 18.20% of the company’s stock.

Institutional investors have recently made changes to their positions in the company. BlackRock Inc. raised its position in shares of Coherus Biosciences by 2.1% during the fourth quarter. BlackRock Inc. now owns 4,722,418 shares of the biotechnology company’s stock worth $42,739,000 after purchasing an additional 94,893 shares during the period. Deutsche Bank AG raised its position in shares of Coherus Biosciences by 30.4% during the fourth quarter. Deutsche Bank AG now owns 2,382,438 shares of the biotechnology company’s stock worth $21,559,000 after purchasing an additional 555,972 shares during the period. Hound Partners LLC raised its position in shares of Coherus Biosciences by 0.3% during the fourth quarter. Hound Partners LLC now owns 2,016,827 shares of the biotechnology company’s stock worth $18,252,000 after purchasing an additional 6,551 shares during the period. Brown Advisory Inc. raised its position in shares of Coherus Biosciences by 1.8% during the fourth quarter. Brown Advisory Inc. now owns 671,103 shares of the biotechnology company’s stock worth $6,074,000 after purchasing an additional 11,837 shares during the period. Finally, Rhenman & Partners Asset Management AB raised its position in shares of Coherus Biosciences by 40.5% during the first quarter. Rhenman & Partners Asset Management AB now owns 451,131 shares of the biotechnology company’s stock worth $6,153,000 after purchasing an additional 130,000 shares during the period. Institutional investors and hedge funds own 99.18% of the company’s stock.

Coherus BioSciences, Inc, a commercial-stage biotherapeutics company, focuses on the biosimilar market worldwide. It markets UDENYCA, a long-acting granulocyte-colony stimulating factor, which stimulates production of granulocytes in order to promote the body's ability to fight infections. The company sells UDENYCA in the United States.

Further Reading: Bear Market – How and Why They Occur

Receive News & Ratings for Coherus Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus Biosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.